Emisphere, Roche sign multi-product research agreement

By Elaine Rigoli

Tampa, Fla., July 18 - Emisphere Technologies, Inc. and Roche Ltd. have entered into a multi-product research collaboration to explore the use of Emisphere's eligen technology in feasibility studies for new oral formulations of a number of Roche molecules.

Roche will fund the research, which will be conducted at both Roche and Emisphere.

"Establishing a research collaboration agreement with Roche to investigate the application of our technology on multiple compounds demonstrates the value Emisphere brings to the product development process. Roche has been working with Emisphere for a number of years and this new agreement further strengthens the relationship between our two companies," Emisphere chairman and chief executive officer Michael M. Goldberg said in a news release.

Emisphere's drug-delivery technology platform, known as the eligen technology, is based on the use of proprietary, synthetic chemical compounds, known as Emisphere delivery agents, or "carriers."

Emisphere is a biopharmaceutical company located in Tarrytown, N.Y.

Roche is a biopharmaceutical company located in Basel, Switzerland.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.